Phosphorylation of troponin I by protein kinase A accelerates relaxation and crossbridge cycle kinetics in mouse ventricular muscle.
Phosphorylation of cardiac myofibrils by cAMP-dependent protein kinase (PKA) can increase the intrinsic rate of myofibrillar relaxation, which may contribute to the shortening of the cardiac twitch during beta-adrenoceptor stimulation. However, it is not known whether the acceleration of myofibrillar relaxation is due to phosphorylation of troponin I (TnI) or of myosin binding protein-C (MyBP-C). To distinguish between these possibilities, we used transgenic mice that overexpress the nonphosphorylatable, slow skeletal isoform of TnI in the myocardium and do not express the normal, phosphorylatable cardiac TNI: The intrinsic rate of relaxation of myofibrils from wild-type and transgenic mice was measured using flash photolysis of diazo-2 to rapidly decrease the [Ca(2+)] within skinned muscles from the mouse ventricles. Incubation with PKA nearly doubled the intrinsic rate of myofibrillar relaxation in muscles from wild-type mice (relaxation half-time fell from approximately 150 to approximately 90 ms at 22 degrees C) but had no effect on the relaxation rate of muscles from the transgenic mice. In parallel studies with intact muscles, we assessed crossbridge kinetics indirectly by determining f(min) (the frequency for minimum dynamic stiffness) during tetanic contractions. Stimulation of beta-adrenoceptors with isoproterenol increased f(min) from 1.9 to 3.1 Hz in muscles from wild-type mice but had no effect on f(min) in muscles from transgenic mice. We conclude that the acceleration of myofibrillar relaxation rate by PKA is due to phosphorylation of TnI, rather than MyBP-C, and that this may be due, at least in part, to faster crossbridge cycle kinetics.
Kentish
J C
JC
Centre for Cardiovascular Biology and Medicine, King's College London, St Thomas' Campus, London, UK. jon.kentish@kcl.ac.uk
McCloskey
D T
DT
Layland
J
J
Palmer
S
S
Leiden
J M
JM
Martin
A F
AF
Solaro
R J
RJ
D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000818:Animals; D002118:Calcium / Q000378:metabolism; D002352:Carrier Proteins / Q000378:metabolism; D002614:Chelating Agents / Q000494:pharmacology; D017868:Cyclic AMP-Dependent Protein Kinases / Q000378:metabolism* / Q000494:pharmacology; D003979:Diazonium Compounds; D006352:Heart Ventricles / Q000187:drug effects / Q000378:metabolism*; D066298:In Vitro Techniques; D007537:Isometric Contraction / Q000187:drug effects / Q000502:physiology; D007545:Isoproterenol / Q000494:pharmacology; D051379:Mice; D008822:Mice, Transgenic; D009200:Myocardial Contraction / Q000187:drug effects / Q000502:physiology*; D009206:Myocardium / Q000378:metabolism; D009210:Myofibrils / Q000187:drug effects / Q000378:metabolism; D010642:Phenoxyacetates; D010766:Phosphorylation; D010782:Photolysis; D011943:Receptors, Adrenergic, beta / Q000378:metabolism; D013314:Stress, Mechanical; D019210:Troponin I / Q000235:genetics / Q000378:metabolism*; D000099163:Myosin Binding Protein C
D000318:Adrenergic beta-Agonists; D002118:Calcium; D002352:Carrier Proteins; D002614:Chelating Agents; D017868:Cyclic AMP-Dependent Protein Kinases; D003979:Diazonium Compounds; D007545:Isoproterenol; D010642:Phenoxyacetates; D011943:Receptors, Adrenergic, beta; D019210:Troponin I; D000099163:Myosin Binding Protein C; C063685:diazo-2